Comparative Pharmacology
Head-to-head clinical analysis: JORNAY PM versus MYDAYIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JORNAY PM versus MYDAYIS.
JORNAY PM vs MYDAYIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylphenidate is a central nervous system (CNS) stimulant. The mode of action in attention deficit hyperactivity disorder (ADHD) is not fully understood, but methylphenidate is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing the levels of these neurotransmitters in the extraneuronal space.
MYDAYIS is a fixed-dose combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mechanism of action in ADHD is not fully elucidated, but they block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase their release into the extraneuronal space.
Initial: 20 mg orally once daily at bedtime; increase by 20 mg weekly as needed; max 100 mg/day.
Oral, 12.5 mg or 25 mg once daily in the morning.
None Documented
None Documented
The terminal elimination half-life of methylphenidate following JORNAY PM administration is approximately 4-5 hours. This relatively short half-life necessitates the delayed-release/extended-release formulation to provide a prolonged duration of effect.
12 hours for d-methylphenidate; 3-4 hours for l-methylphenidate; clinical context: d-isomer provides extended coverage; l-isomer contributes minimal activity
Methylphenidate and its metabolites are primarily excreted in urine (approximately 90%) as metabolites (mainly ritalinic acid) with about 2% unchanged parent drug. Fecal excretion accounts for <1%.
Renal (approx. 90% as unchanged drug and 10% as inactive metabolites); fecal <5%
Category C
Category C
CNS Stimulant
CNS Stimulant